T2 Biosystems, Inc. (TTOO)
TTOO Stock Price Chart
Explore T2 Biosystems, Inc. interactive price chart. Choose custom timeframes to analyze TTOO price movements and trends.
TTOO Company Profile
Discover essential business fundamentals and corporate details for T2 Biosystems, Inc. (TTOO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
7 Aug 2014
Employees
113.00
Website
https://www.t2biosystems.comCEO
Craig R. Jalbert CIRA
Description
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
TTOO Financial Timeline
Browse a chronological timeline of T2 Biosystems, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Oct 2025
Earnings released on 4 Jun 2025
Earnings released on 29 May 2025
Earnings released on 28 Mar 2025
Earnings released on 14 Nov 2024
EPS came in at -$0.57 surpassing the estimated -$0.64 by +10.94%, while revenue for the quarter reached $1.99M , missing expectations by -29.11%.
Earnings released on 29 Jul 2024
EPS came in at -$0.66 surpassing the estimated -$0.97 by +31.96%, while revenue for the quarter reached $1.95M , missing expectations by -7.05%.
Earnings released on 6 May 2024
EPS came in at -$2.66 falling short of the estimated -$1.86 by -43.01%, while revenue for the quarter reached $2.06M , beating expectations by +22.75%.
Earnings released on 20 Mar 2024
EPS came in at -$3.45 surpassing the estimated -$3.85 by +10.39%, while revenue for the quarter reached $1.68M , missing expectations by -16.05%.
Earnings released on 14 Nov 2023
EPS came in at -$3.45 surpassing the estimated -$3.85 by +10.39%, while revenue for the quarter reached $1.47M , missing expectations by -38.67%.
Stock split effective on 13 Oct 2023
Shares were split 1 : 100 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Aug 2023
EPS came in at -$8.00 falling short of the estimated -$0.27 by -2.86K%, while revenue for the quarter reached $1.96M , missing expectations by -3.25%.
Earnings released on 23 May 2023
EPS came in at -$117.00 falling short of the estimated -$1.20 by -9.65K%, while revenue for the quarter reached $2.08M , missing expectations by -19.14%.
Earnings released on 13 Mar 2023
EPS came in at -$1.41 surpassing the estimated -$1.70 by +17.06%, while revenue for the quarter reached $5.48M , beating expectations by +1.54%.
Earnings released on 10 Nov 2022
EPS came in at -$295.00 falling short of the estimated -$2.04 by -14.36K%, while revenue for the quarter reached $3.68M , missing expectations by -22.14%.
Stock split effective on 13 Oct 2022
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 Aug 2022
EPS came in at -$500.00 falling short of the estimated -$4.50 by -11.01K%, while revenue for the quarter reached $5.91M , missing expectations by -3.69%.
Earnings released on 5 May 2022
EPS came in at -$500.00 falling short of the estimated -$3.50 by -14.19K%, while revenue for the quarter reached $7.23M , beating expectations by +8.74%.
Earnings released on 17 Feb 2022
EPS came in at -$350.00 falling short of the estimated -$4.50 by -7.68K%, while revenue for the quarter reached $6.98M , beating expectations by +12.84%.
Earnings released on 4 Nov 2021
EPS came in at -$400.00 falling short of the estimated -$4.00 by -9.90K%, while revenue for the quarter reached $7.43M , beating expectations by +32.17%.
Earnings released on 5 Aug 2021
EPS came in at -$400.00 matching the estimated -$400.00, while revenue for the quarter reached $6.69M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at -$350.00 matching the estimated -$350.00, while revenue for the quarter reached $6.96M , meeting expectations.
Earnings released on 4 Mar 2021
EPS came in at -$350.00 falling short of the estimated -$300.00 by -16.67%, while revenue for the quarter reached $7.79M .
Earnings released on 4 Nov 2020
EPS came in at -$400.00 surpassing the estimated -$500.00 by +20.00%, while revenue for the quarter reached $5.25M , beating expectations by +3.44K%.
TTOO Stock Performance
Access detailed TTOO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.